Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program (aSAH-Omics) ：A Multicenter Clinical and Mechanistic Study
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Xiaolin Chen, MD
- Enrollment
- 2,000
- Locations
- 1
- Primary Endpoint
- Modified Rankin Scale (mRS) score for functional outcome
Overview
Brief Summary
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening cerebrovascular emergency with high mortality and disability rates. Despite advances in neuroimaging and interventional techniques, outcomes remain poor for many patients due to complex post-rupture complications such as delayed cerebral ischemia (DCI), pneumonia, and other systemic injuries. These secondary events critically affect neurological recovery, yet their molecular mechanisms are not fully understood.
This multicenter study aims to investigate the biological basis of post-rupture complications and prognosis in patients with aSAH through integrated multi-omics and clinical data analysis. Biospecimens including blood, cerebrospinal fluid, urine, and other relevant tissues will be collected for genomic, transcriptomic, proteomic, metabolomic, and imaging-omic profiling. By linking molecular data with clinical and imaging indicators, the study seeks to identify key pathways and biomarkers associated with secondary injury and outcome heterogeneity.
Detailed Description
Aneurysmal subarachnoid hemorrhage (aSAH) is a severe cerebrovascular emergency caused by the rupture of an intracranial aneurysm. Despite advances in neuroimaging and microsurgical or endovascular techniques, aSAH remains associated with high mortality and long-term disability. Post-rupture complications-such as delayed cerebral ischemia (DCI), pneumonia, and other systemic complications-are major determinants of neurological recovery and prognosis.
Following aneurysm rupture, a cascade of complex secondary injuries is triggered, critically influencing clinical outcomes. Beyond the initial hemorrhagic insult, secondary pathophysiological processes-including neuroinflammation, endothelial dysfunction, and blood-brain barrier disruption-play pivotal roles in mediating delayed brain injury and neurological deterioration. However, how these biological processes interact and contribute to heterogeneous outcomes remains poorly understood.
This multicenter study aims to elucidate the molecular mechanisms underlying post-rupture complications and prognosis in aSAH through integrative multi-omics and clinical data analysis. By combining genomic, transcriptomic, proteomic, metabolomic, and imaging-omic approaches using biospecimens such as blood, cerebrospinal fluid, urine, and other relevant tissues, this project seeks to identify key molecular pathways and biomarkers associated with secondary injury and outcome variation. The findings are expected to provide systematic insights into the biological basis of aSAH progression and establish a foundation for precision prediction and individualized management.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Adult patients aged ≥18 years;
- •Confirmed diagnosis of aneurysmal subarachnoid hemorrhage (aSAH) by CTA, or DSA;
- •Aneurysm secured by either microsurgical clipping or endovascular coiling during hospitalization;
- •Time from onset to aneurysm treatment ≤ 72 hours;
- •Availability of biospecimens, including blood, cerebrospinal fluid (CSF), urine, or fecal samples collected during hospitalization;
- •Signed informed consent obtained from the patient or legal representative.
Exclusion Criteria
- •History of previous intracranial aneurysm surgery or embolization;
- •Non-aneurysmal SAH, traumatic SAH, or perimesencephalic non-aneurysmal hemorrhage;
- •Presence of malignancy, severe hepatic or renal dysfunction, or other systemic diseases that may affect survival or biomarker expression;
- •Severe cardiorespiratory insufficiency or unstable medical condition precluding study participation;
- •Pregnancy or lactation;
- •Refusal to participate or withdrawal of consent.
Outcomes
Primary Outcomes
Modified Rankin Scale (mRS) score for functional outcome
Time Frame: 3, 6, and 12 months after onset
Functional outcome will be evaluated using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death). Higher scores indicate greater disability. The distribution of mRS scores will be analyzed at predefined follow-up time points.
Secondary Outcomes
- Incidence of anemia(After onset, up to 30 days)
- Incidence of pneumonia(From enrollment to the end of follow-up at 3 months)
- Incidence of rebleeding(After onset, up to 30 days)
- Incidence of delayed cerebral ischemia (DCI)(After onset, up to 30 days)
- Incidence of deep vein thrombosis (DVT)(After onset, up to 30 days)
Investigators
Xiaolin Chen, MD
Prof.
Beijing Tiantan Hospital